STRW trades 17.5% below Wall Street's consensus target of $15.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STRW achieves its forward estimates and maintains a stable P/E multiple of 19.7x. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Strawberry Fields REIT LLC (STRW) has a Wall Street consensus price target of $15.67, based on estimates from 3 covering analysts. With the stock currently trading at $13.34, this represents a potential upside of +17.5%. The company has a market capitalization of $179M.
Analyst price targets range from a low of $15.00 to a high of $16.00, representing a 6% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, STRW trades at a trailing P/E of 22.2x and forward P/E of 19.7x. Analysts expect EPS to grow -60.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $80.50, with bear and bull scenarios of $50.72 and $106.07 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SBRASabra Health Care REIT, Inc. | $4.6B | $18.12 | $21.00 | +15.9% | Hold | 26.9x | 29 |
CTRECareTrust REIT, Inc. | $8.8B | $37.06 | $44.25 | +19.4% | Buy | 24.8x | 19 |
LTCLTC Properties, Inc. | $1.9B | $36.37 | $36.00 | -1.0% | Hold | 19.4x | 22 |
GMREGlobal Medical REIT Inc. | $94M | $35.74 | $40.00 | +11.9% | Buy | 595.7x | 22 |
OHIOmega Healthcare Investors, Inc. | $13.3B | $44.53 | $50.43 | +13.2% | Hold | 22.4x | 28 |
NHINational Health Investors, Inc. | $3.4B | $70.82 | $83.40 | +17.8% | Hold | 19.9x | 18 |
WELLWelltower Inc. | $144.8B | $206.65 | $237.80 | +15.1% | Buy | 71.3x | 34 |
VTRVentas, Inc. | $38.8B | $81.61 | $95.86 | +17.5% | Buy | 130.8x | 32 |
HRHealthcare Realty Trust Incorporated | $6.9B | $19.79 | $21.83 | +10.3% | Hold | — | 30 |
EHCEncompass Health Corporation | $9.7B | $98.03 | $146.00 | +48.9% | Buy | 16.3x | 26 |
Quick answers to the most common questions about buying STRW stock.
Strawberry Fields REIT LLC (STRW) has a consensus 12-month price target of $15.67, implying 17.5% upside from $13.34. The 3 analysts covering STRW see moderate appreciation potential.
STRW has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $15.67 implies 17.5% upside from current levels.
With a forward P/E of 19.7337x, STRW trades at a relatively low valuation. The consensus target of $15.67 implies 17.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $16 for STRW, while the most conservative target is $15. The consensus of $15.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $106 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
STRW is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STRW stock forecast based on 3 Wall Street analysts shows a consensus price target of $15.67, with estimates ranging from $15 (bear case) to $16 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $81, with bear/bull scenarios of $51/$106.
Our quantitative valuation model calculates STRW's fair value at $81 (base case), with a bear case of $51 and bull case of $106. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
STRW trades at a forward P/E ratio of 19.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 22.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on STRW, with a "Buy" consensus rating and $15.67 price target (17.5% upside). 2 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STRW analyst price targets range from $15 to $16, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $15.67 consensus represents the middle ground. Our model's $51-$106 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.